These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 21230010)

  • 1. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
    Sahoo N; Manchikanti P
    BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herbal drug patenting in India: IP potential.
    Sahoo N; Manchikanti P; Dey SH
    J Ethnopharmacol; 2011 Sep; 137(1):289-97. PubMed ID: 21640810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. With the help of a foreign ally: biopharmaceutical innovation in India after TRIPS.
    Angeli F
    Health Policy Plan; 2014 May; 29(3):280-91. PubMed ID: 23558959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation.
    Malhotra H
    Biologicals; 2011 Sep; 39(5):321-4. PubMed ID: 21784652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herbal drug regulation and commercialization: an Indian industry perspective.
    Sahoo N; Manchikanti P
    J Altern Complement Med; 2013 Dec; 19(12):957-63. PubMed ID: 23829812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Indian manufacturer's perspective for harmonization of guidelines for similar biotherapeutic products.
    Babu PV
    Biologicals; 2011 Sep; 39(5):300-3. PubMed ID: 21816621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The regulatory framework for similar biotherapeutic products in Cuba.
    Hechavarría Núñez Y; Pérez Massipe RO; Orta Hernández SD; Muñoz LM; Jacobo Casanueva OL; Pérez Rodríguez V; Domínguez Morales RB; Pérez Cristiá RB
    Biologicals; 2011 Sep; 39(5):317-20. PubMed ID: 21930393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-engineering drug discovery and development.
    FitzGerald GA
    LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards regulation of similar biotherapeutic products: Thailand's perspective.
    Thanaphollert P; Tungsanga K
    Biologicals; 2011 Sep; 39(5):346-7. PubMed ID: 21917474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of benchmarking in the development of biopharmaceutical products.
    Giffin M; McLeish S
    Biotechnol Annu Rev; 2003; 9():279-84. PubMed ID: 14650932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Registration of similar biological products--Singapore's approach.
    Poh J; Tam KT
    Biologicals; 2011 Sep; 39(5):343-5. PubMed ID: 21783381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Industry views of biosimilar development in Japan.
    Horikawa H; Tsubouchi M; Kawakami K
    Health Policy; 2009 Jul; 91(2):189-94. PubMed ID: 19157628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patent watch: Drug patenting in India: looking back and looking forward.
    Sampat BN; Shadlen KC
    Nat Rev Drug Discov; 2015 Aug; 14(8):519-20. PubMed ID: 26184492
    [No Abstract]   [Full Text] [Related]  

  • 16. China's perspective on similar biotherapeutic products.
    Liang C; Wang J
    Biologicals; 2011 Sep; 39(5):312-6. PubMed ID: 21924622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicologic pathology in a multicultural world--India.
    Schultze AE; Reddy VR; Donnelly KB; Berridge BR
    Toxicol Pathol; 2011 Oct; 39(6):1003-9. PubMed ID: 21859882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current regulatory and scientific considerations for approving biosimilars in Iran.
    Hadavand N; Valadkhani M; Zarbakhsh A
    Biologicals; 2011 Sep; 39(5):325-7. PubMed ID: 21873077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
    Farid SS; Baron M; Stamatis C; Nie W; Coffman J
    MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The requirements for manufacturing highly active or sensitising drugs comparing Good Manufacturing Practices.
    Petrelli F; Caraffa A; Scuri S; Grappasonni I; Magrini E; Cocchini A
    Acta Biomed; 2019 May; 90(2):288-299. PubMed ID: 31125009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.